Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA.
Oct 20, 2016
Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting
Oct 19, 2016
Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira
Sep 21, 2016 at 2:30 PM PT
Sep 13, 2016 at 2:55 PM ET